CXI-benzo-84 reversibly binds to tubulin at colchicine site and induces apoptosis in cancer cells

Biochemical Pharmacology

Volumn 86, Issue 3, 2013, Pages 378-391

  Rai, Ankit ^a   Gupta, Tilak Kumar ^a   Kini, Sudarshan ^a   Kunwar, Ambarish ^a   Surolia, Avadhesha ^b   Panda, Dulal ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Anticancer drug; Apoptosis; Benzimidazole; Cell cycle; Checkpoint proteins; Microtubule assembly dynamics

Indexed keywords

ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; BUB1 RELATED PROTEIN; COLCHICINE; CXI BENZO 84; GUANOSINE TRIPHOSPHATASE; PROTEIN MAD2; TUBULIN; UNCLASSIFIED DRUG; ANILIDE; BENZIMIDAZOLE; DIMETHYL SULFOXIDE; EGTAZIC ACID; GUANOSINE TRIPHOSPHATE; N (2 (PIPERIDIN 1 YL)PHENYL) 2 (THIOPHEN 2 YL) 1H BENZO(D)IMIDAZOLE 4 CARBOXAMIDE; N-(2-(PIPERIDIN-1-YL)PHENYL)-2-(THIOPHEN-2-YL)-1H-BENZO(D)IMIDAZOLE-4-CARBOXAMIDE; PHOSPHATE BUFFERED SALINE; PROPIDIUM IODIDE; SULFORHODAMINE B;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL; CELL SCREENING; CENTROMERE; CONTROLLED STUDY; DRUG BINDING; DRUG INHIBITION; DRUG POTENCY; DRUG SCREENING; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERPHASE; METAPHASE; MITOSIS; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; (N-(2-(PIPERIDIN-1-YL)PHENYL)-2-(THIOPHEN-2-YL)-1H-BENZO[D]IMIDAZOLE-4-CARBOXAMIDE); ANIMAL; CELL CYCLE; CELL STRAIN MCF 7; CHECKPOINT PROTEINS; CHEMISTRY; CXI-BENZO-84; DAMA-COLCHICINE; DRUG EFFECT; ETHYLENE GLYCOL-BIS(2-AMINOETHYLETHER)-N,N,N′,N′-TETRAACETIC ACID; GUANOSINE-5′-TRIPHOSPHATE; HELA CELL; METABOLISM; MICROTUBULE ASSEMBLY DYNAMICS; N-DEACETYL-N-(2-MERCAPTOACETYL) COLCHICINE; PBS; PHYSIOLOGY; PI; PIPERAZINE-N,N′-BIS(2-ETHANESULFONIC ACID); PIPES; SRB; TCA; TRICHLORO ACETIC ACID; TUMOR CELL LINE;

(N-(2-(PIPERIDIN-1-YL)PHENYL)-2-(THIOPHEN-2-YL)-1H-BENZO[D]IMIDAZOLE-4-CARBOXAMIDE); ANTICANCER DRUG; APOPTOSIS; BENZIMIDAZOLE; CELL CYCLE; CHECKPOINT PROTEINS; CXI-BENZO-84; DAMA-COLCHICINE; DIMETHYL SULFOXIDE; DMSO; EGTA; ETHYLENE GLYCOL-BIS(2-AMINOETHYLETHER)-N,N,N′,N′-TETRAACETIC ACID; GTP; GUANOSINE-5′-TRIPHOSPHATE; MICROTUBULE ASSEMBLY DYNAMICS; N-DEACETYL-N-(2-MERCAPTOACETYL) COLCHICINE; PBS; PHOSPHATE BUFFERED SALINE; PI; PIPERAZINE-N,N′-BIS(2-ETHANESULFONIC ACID); PIPES; PROPIDIUM IODIDE; SRB; SULFORHODAMINE B; TCA; TRICHLORO ACETIC ACID;

ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZIMIDAZOLES; BINDING SITES; CELL LINE, TUMOR; COLCHICINE; HELA CELLS; HUMANS; MCF-7 CELLS; MICE; TUBULIN;

EID: 84884576648     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.05.024     Document Type: Article

References (65)

1. Walia R, Hedaitullah M, Naaz SF, Iqbal K, Lamba HS. Benzimidazloe derivatives - an overview. Int J Res Pharm Chem 2011;1:565-74.
2. Bansal Y, Silakari OT. The therapeutic journey of benzimidazoles: a review. Bioorg Med Chem 2012;20:6208-36.
3. Wang LH, Peck RW, Yin Y, Allanson J, Wiggs R, Wire MB. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2003;47:1334-42. (Pubitemid 36368594)
4. El Rashedy AA, Aboul-Enein HY. Benzimidazole derivatives as potential anticancer agents. Mini Rev Med Chem 2013;13:399-407.
5. Tong Y, Bouska JJ, Ellis PA, Johnson EF, Leverson J, Liu X, et al. Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents. J Med Chem 2009;12(52):6803-13.
6. Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 2007;6:945-56. (Pubitemid 46554564)
7. Certal V, Halley F, Virone-Oddos A, Delorme C, Karlsson A, Rak A, et al. Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kb inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers. J Med Chem 2012;55:4788-805.
8. Sheth PR, Shipps Jr GW, Seghezzi W, Smith CK, Chuang CC, Sanden D, et al. Novel benzimidazole inhibitors bind to a unique site in the kinesin spindle protein motor domain. Biochemistry 2010;49:8350-8.
9. Feng R, Li S, Lu C, Andreas C, Stolz DB, Mapara MY, et al. Targeting the microtubular network as a new antimyeloma strategy. Mol Cancer Ther 2011;10:1886-96.
10. De Brabander MJ, Van de Veire RM, Aerts FE, Borgers M, Janssen PA. The effects of methyl (5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl) carbamate, (R 17934; NSC 238159), a new synthetic antitumoral drug interfering with microtubules, on mammalian cells cultured in vitro. Cancer Res 1976;36: 905-16.
11. Davidse LC. Benzimidazole fungicides-mechanism of action and biological impact. Annu Rev Phytopathol 1986;4:43-65.
12. Rathinasamy K, Panda D. Kinetic stabilization of microtubule dynamic instability by benomyl increases the nuclear transport of p53. Biochem Pharmacol 2008;76:1669-80.
13. Musch A. Microtubule organization and function in epithelial cells. Traffic 2004;5:1-9. (Pubitemid 38159399)
14. Lam JK, Armes SP, Stolnik S. The involvement of microtubules and actin filaments in the intracellular transport of non-viral gene delivery system. J Drug Target 2011;19:56-66.
15. Kapoor S, Panda D. Kinetic stabilization of microtubule dynamics by indanocine perturbs EB1 localization, induces defects in cell polarity and inhibits migration of MDA-MB-231 cells. Biochem Pharmacol 2012;83:1495-506.
16. Singh P, Rathinasamy K, Mohan R, Panda D. Microtubule assembly dynamics: an attractive target for anticancer drugs. IUBMB Life 2008;60:368-75.
17. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010;9:790-803.
18. Wang LG, Liu XM, Kreis W, Budman DR. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999;44:355-61. (Pubitemid 29455579)
19. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003;22:9075-86. (Pubitemid 38121708)
20. Mohan R, Panda D. Kinetic stabilization of microtubule dynamics by estramustine is associated with tubulin acetylation, spindle abnormalities, and mitotic arrest. Cancer Res 2008;68:6181-9.
21. Rai A, Surolia A, Panda D. An antitubulin agent BCFMT inhibits proliferation of cancer cells and induces cell death by inhibiting microtubule dynamics. PLoS ONE 2012;7:e44311.
22. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;4(82):1107-12. (Pubitemid 20213250)
23. Gupta K, Panda D. Perturbation of microtubule polymerization by quercetin through tubulin binding: a novel mechanism of its antiproliferative activity. Biochemistry 2002;41:13029-38. (Pubitemid 35215787)
24. Panda D, Rathinasamy K, Santra MK, Wilson L. Kinetic suppression of microtubule dynamic instability by griseofulvin: implications for its possible use in the treatment of cancer. Proc Natl Acad Sci U S A 2005;102:9878-83. (Pubitemid 40993661)
25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
26. Geladopoulos TP, Sotiroudis TG, Evangelopoulos AE. A malachite green colorimetric assay for protein phosphatase activity. Anal Biochem 1991;192:112-6.
27. Bhattacharyya B, Kapoor S, Panda D. Fluorescence spectroscopic methods to analyze drug-tubulin interactions. Methods Cell Biol 2010;95:301-29.
28. Mas MT, Colman RF. Spectroscopic studies of the interactions of coenzymes and coenzyme fragments with pig heart, oxidized triphosphopyridine nucleotide specific isocitrate dehydrogenase. Biochemistry 1985;24:1634-46. (Pubitemid 15089157)
29. Dixon M. The determination of enzyme inhibitor constants. Biochem J 1953;55: 170-1.
30. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785-91.
31. Sousa SF, Fernandes PA, Ramos MJ. Protein-ligand docking: current status and future challenges. Proteins 2006;65:15-26. (Pubitemid 44320611)
32. Schuttelkopf AW, van Aalten DM. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 2004;60:1355-63. (Pubitemid 41079731)
33. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004;428:198-202. (Pubitemid 38374318)
34. Chiang YK, Kuo CC, Wu YS, Chen CT, Coumar MS, Wu JS, et al. Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity. J Med Chem 2009;52: 4221-33.
35. Alvarez R, Alvarez C, Mollinedo F, Sierra BG, Medarde M, Pelaez R. Isocombretastatins A: 1,1-diarylethenes as potent inhibitors of tubulin polymerization and cytotoxic compounds. Bioorg Med Chem 2009;17:6422-31.
36. Dorleans A, Gigant B, Ravelli RB, Mailliet P, Mikol V, Knossow M. Variations in the colchicine-binding domain provide insight into the structural switch of tubulin. Proc Natl Acad Sci U S A 2009;106:13775-79.
37. Hetenyi C, van der Spoel D. Efficient docking of peptides to proteins without prior knowledge of the binding site. Protein Sci 2002;11:1729-37. (Pubitemid 34663553)
38. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera - a visualization system for exploratory research and analysis. J Comput Chem 2004;25:1605-12.
39. Cortese F, Bhattacharyya B, Wolff J. Podophyllotoxin as a probe for the colchicine binding site of tubulin. J Biol Chem 1977;252:1134-40. (Pubitemid 8071267)
40. Hyman AA, Salser S, Drechsel DN, Unwin N, Mitchison TJ. Role of GTP hydrolysis in microtubule dynamics: information from a slowly hydrolyzable analogue, GMPCPP. Mol Biol Cell 1992;3:1155-67. (Pubitemid 23088965)
41. Chakraborti S, Chakravarty D, Gupta S, Chatterji BP, Dhar G, Poddar A, et al. Discrimination of ligands with different flexibilities resulting from the plasticity of the binding site in tubulin. Biochemistry 2012;51:7138-48.
42. Chakrabarti G, Sengupta S, Bhattacharyya B. Thermodynamics of colchicinoid- tubulin interactions. Role of B-ring and C-7 substituent. J Biol Chem 1996;271: 2897-901.
43. Kukol A. Molecular modeling of proteins. In: Methods in molecular biology. Totowa, NJ: Humana Press; 2008. 443.
44. Mills JE, Dean PM. Three-dimensional hydrogen-bond geometry and probability information from a crystal survey. J Comput Aided Mol Des 1996;10: 607-22. (Pubitemid 126712453)
45. DeLano. The PyMOL molecular genetics graphics system. San Carlos, CA: DeLano Scientific LLC; 2002.
46. Babu MM. NCI: A server to identify non-canonical interactions in protein structures. Nucleic Acids Res 2003;31:3345-8.
47. Kaur H, Raghava GP. Prediction of C alpha-H. . .O and C alpha-H. . .pi interactions in proteins using recurrent neural network. In Silico Biol 2006;6: 111-25. (Pubitemid 43905161)
48. Suezawa H, Ishihara S, Umezawa Y, Tsuboyama S, Nishio M. The Aromatic CH- p hydrogen bond as an important factor in determining the relative stability of diastereomeric salts relevant to enantiomeric resolution-A crystallographic database study. Eur J Org Chem 2004;23:4816-22. (Pubitemid 40006819)
49. Devereux M, McCann M, Shea DO, Kelly R, Egan D, Deegan C, et al. Synthesis, antimicrobial activity and chemotherapeutic potential of inorganic derivatives of 2-(40-thiazolyl)benzimidazole[thiabendazole]: X-ray crystal structures of [Cu(TBZH)2Cl]Cl.H2O.EtOH and TBZH2NO3 (TBZH = thiabendazole). J Inorg Biochem 2004;98:1023-31. (Pubitemid 38638500)
50. Yenjerla M, Cox C, Wilson L, Jordan MA. Carbendazim inhibits cancer cell proliferation by suppressing microtubule dynamics. J Pharmacol Exp Ther 2009;328:390-8.
51. Ray S, Mohan R, Singh JK, Samantaray MK, Shaikh MM, Panda D, et al. Anticancer and antimicrobial metallopharmaceutical agents based on palladium, gold, and silver N-heterocyclic carbene complexes. J Am Chem Soc 2007;129:15042-53. (Pubitemid 350237567)
52. Banerjee M, Singh P, Panda D. Curcumin suppresses the dynamic instability of microtubules, activates the mitotic checkpoint and induces apoptosis in MCF- 7 cells. FEBS J 2010;277:3437-48.
53. Reeve JG, Wright KA, Rabbitts PH, Twentyman PR, Koch G. Collateral resistance to verapamil in multidrug-resistant mouse tumor cells. J Natl Cancer Inst 1989;81:1588-90. (Pubitemid 19253311)
54. Coley HM, Twentyman PR, Workman P. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem Pharmacol 1989;38(15):4467-75. (Pubitemid 20027547)
55. Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 2001;61:749-58. (Pubitemid 32128642)
56. Koch G, Smith M, Twentyman P, Wright K. Identification of a novel calciumbinding protein (CP22) in multidrug-resistant murine and hamster cells. FEBS Lett 1986;195:275-9. (Pubitemid 16049005)
57. Barrand MA, Twentyman PR. Differential recognition of mdr1a and mdr1b gene products in multidrug resistant mouse tumour cell lines by different monoclonal antibodies. Br J Cancer 1992;65:239-45.
58. Lee JC, Harrison D, Timasheff SN. Interaction of vinblastine with calf brain microtubule protein. J Biol Chem 1975;250:9276-82.
59. Cruz-Monserrate Z, Mullaney JT, Harran PG, Pettit GR, Hamel E. Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography. Eur J Biochem 2003;270:3822-8. (Pubitemid 37123254)
60. Panda D, Roy S, Bhattacharyya B. Reversible dimer dissociation of tubulin S and tubulin detected by fluorescence anisotropy. Biochemistry 1992;31:9709-16.
61. Wilson L. Microtubules as drug receptors: pharmacological properties of microtubule protein. Ann N Y Acad Sci 1975;253:213-31.
62. Tirnauer JS, Bierer BE. EB1 proteins regulate microtubule dynamics, cell polarity, and chromosome stability. J Cell Biol 2000;149:761-6. (Pubitemid 30327228)
63. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65. (Pubitemid 38525281)
64. Margolis RL, Wilson L. Addition of colchicine-tubulin complex to microtubule ends: the mechanism of substoichiometric colchicine poisoning. Proc Natl Acad Sci U S A 1977;74:3466-70. (Pubitemid 8177798)
65. Pagano A, HonoreS, Mohan R, Berges R, Akhmanova A, Braguer D. Epothilone B inhibits migration of glioblastoma cells by inducing microtubule catastrophes and affecting EB1 accumulation at microtubule plus ends. Biochem Pharmacol 2012;84:432-43.